LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, completed the merger with Graphite Bio, a biotech company, in a $225m deal. Transaction includes a PIPE investment from Versant Ventures, RA Capital Management, Alpha Wave, Point72, Samsara BioCapital, Sectoral Asset Management, and RTW Investments. “Following the close of this transaction, we believe we are well-positioned to bring the opportunity of a once-daily pharmacological eye drop intended to improve near vision throughout the full workday closer to the 128m people in the United States who are impacted by presbyopia,” Eef Schimmelpennink, LENZ Therapeutics President and CEO.